MSLN and cancer: The anti-mesothelin (MSLN) ADC consists of three moieties: the antibody that recognizes MSLN, a protein that is over-expressed on cell surfaces in several types of cancer [41], monomethyl auristatin E (MMAE), a potent cytotoxic agent that can depolymerize microtubules and prevent cell division, and a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-VC-PAB), that joins the antibody and MMAE together.